SEC Form 4 · accession 0001209191-19-017822
GLOBUS MEDICAL INC · GMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony L Williams
Officer — President
Period of report
Mar 5, 2019
Accepted (ET)
Mar 7, 2019 · 5:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001237831
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Mar 5, 2019 | M | 89,583 | $25.65 | A | 89,583 | D | |
| Class A Common Stock | Mar 5, 2019 | M | 47,500 | $25.52 | A | 137,083 | D | |
| Class A Common Stock | Mar 5, 2019 | M | 20,454 | $43.77 | A | 157,537 | D | |
| Class A Common Stock | Mar 5, 2019 | M | 8,333 | $24.10 | A | 165,870 | D | |
| Class A Common StockF1 | Mar 5, 2019 | S | 165,870 | $47.05 | D | 0 | D | |
| Class A Common Stock | Mar 6, 2019 | M | 2,879 | $43.77 | A | 2,879 | D | |
| Class A Common Stock | Mar 6, 2019 | M | 5,507 | $26.27 | A | 8,386 | D | |
| Class A Common StockF2 | Mar 6, 2019 | S | 8,386 | $46.14 | D | 0 | D | |
| Class A Common Stock | Mar 7, 2019 | M | 37,826 | $26.27 | A | 37,826 | D | |
| Class A Common StockF3 | Mar 7, 2019 | S | 37,826 | $46.01 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy Class A Common Stock)F4 | $25.65 | Mar 5, 2019 | M | 89,583 | D | — | Jul 7, 2025 | Class A Common Stock | 89,583 | 10,417 | D |
| Stock Option (Right to Buy Class A Common Stock)F5 | $25.52 | Mar 5, 2019 | M | 47,500 | D | — | Jan 25, 2026 | Class A Common Stock | 47,500 | 12,500 | D |
| Stock Option (Right to Buy Class A Common Stock)F6 | $43.77 | Mar 5, 2019 | M | 20,454 | D | — | Jan 22, 2028 | Class A Common Stock | 20,454 | 59,546 | D |
| Stock Option (Right to Buy Class A Common Stock)F7 | $24.10 | Mar 5, 2019 | M | 8,333 | D | — | Jan 20, 2025 | Class A Common Stock | 8,333 | 0 | D |
| Stock Option (Right to Buy Class A Common Stock)F6 | $43.77 | Mar 6, 2019 | M | 2,879 | D | — | Jan 22, 2028 | Class A Common Stock | 2,879 | 56,667 | D |
| Stock Option (Right to Buy Class A Common Stock)F8 | $26.27 | Mar 6, 2019 | M | 5,507 | D | — | Jan 30, 2027 | Class A Common Stock | 5,507 | 74,493 | D |
| Stock Option (Right to Buy Class A Common Stock)F8 | $26.27 | Mar 7, 2019 | M | 37,826 | D | — | Jan 30, 2027 | Class A Common Stock | 37,826 | 36,667 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.80 to $47.40, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.89, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.09, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- F4These options were granted on July 7, 2015, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on July 7, 2016, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
- F5These options were granted on January 25, 2016, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2017, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
- F6These options were granted on January 22, 2018, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2019, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
- F7These options were granted on January 20, 2015, and vested over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2016, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
- F8These options were granted on January 30, 2017, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2018, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.